277 related articles for article (PubMed ID: 31840838)
1. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
Mukai M; Mould D; Maeda H; Narushima K; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
[TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
4. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
5. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
7. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
8. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
9. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
10. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
13. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
15. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
[TBL] [Abstract][Full Text] [Related]
19. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
